STOCKHOLM, December 16, 2025 /PRNewswire/ — Affibody AB (“Affibody”) today announced that the Trial Review Committee (TRC) has recommended to advance the Phase STOCKHOLM, December 16, 2025 /PRNewswire/ — Affibody AB (“Affibody”) today announced that the Trial Review Committee (TRC) has recommended to advance the Phase

Affibody Accelerates Phase 1 Study with ABY-271 Following Initial Patient Data

STOCKHOLM, December 16, 2025 /PRNewswire/ — Affibody AB (“Affibody”) today announced that the Trial Review Committee (TRC) has recommended to advance the Phase I clinical study with the Radioligand Therapy (RLT) candidate ABY-271 in HER2-positive metastatic breast cancer to its second part, where higher radioactivity levels will be evaluated. 

The TRC has based its positive recommendation on safety, tolerability, dosimetry and biodistribution data from the first enrolled cohort of patients, demonstrating tumor targeting and a favorable safety profile with low uptake in kidneys and other critical organs.

“The initial data from the ABY-271 study are very promising. We observed a favorable safety profile and encouraging biodistribution data, supporting progression of the study to the next stage,” said assistant professor Oscar Wiklander at the Karolinska University Hospital, coordinating investigator in the study. “These results offer important insight into how the therapy behaves in patients, and we are eager to advance the study to deepen our understanding of its clinical potential.”

“I am thrilled that these early clinical results with ABY-271 mirror the preclinical findings and dosimetry predictions remarkably well. I am especially excited about the low kidney uptake,” said David Bejker, CEO of Affibody. “The positive outcome not only marks an important milestone for this program but also for the Affibody® platform as a powerful technology for developing next-generation targeted radiotherapeutics.”

ABY-271 is an Affibody® molecule that targets HER2-expressing tumors and is labeled with the radioisotope lutetium-177, which emits cytotoxic beta radiation exerting irreversible damage to the tumor cells. Affibody is evaluating ABY-271 in a first-in-human, open-label, two-stage, randomized Phase 1 clinical study to assess the safety, tolerability, and biodistribution of ABY-271 in tumors and critical organs in subjects with HER2-positive metastatic breast cancer. The study is conducted at sites specialized in breast cancer and nuclear medicine in Sweden and Germany.

The TRC, including principal investigators, medical monitor, dosimetry and nuclear medicine specialists, has reviewed safety, tolerability, dosimetry and biodistribution data from a pre-specified number of enrolled patients. The TRC confirmed favorable safety and biodistribution, with low uptake in kidneys and other critical organs. The TRC recommends advancing the study to part B, which will evaluate higher radioactivity levels and additional protein mass doses. In line with this recommendation, Affibody will submit a protocol amendment to the European Medicines Agency (EMA) to accelerate the transition to the second part, which is expected to start in H1 2026 with the first results anticipated in H2 2026.

About the Phase 1 clinical study

The clinical study is a Phase 1, open-label, two-stage, randomized trial to assess the safety, tolerability, and biodistribution of ABY-271 in tumors and critical organs in subjects with HER2-positive metastatic breast cancer.

The trial consists of two parts, part A in which the uptake of ABY-271 in tumors and critical organs will be evaluated in up to six sequentially enrolled patients, and part B in which higher radioactivity levels and additional protein mass doses for subsequent clinical trials will be evaluated in a total of 15 randomized patients. Patients will receive a single intravenous infusion of ABY-271 in both part A and part B. Dr Oscar Wiklander at Karolinska University Hospital is the coordinating investigator in Sweden. More information about the study can be found on clinicaltrials.gov under NCT07081555.

About Affibody

Affibody is a clinical stage radiopharmaceutical company developing next generation radioligand therapies (RLTs) designed to deliver highly selective tumor targeting across a wide range of cancers. Leveraging decades of innovation in Affibody® molecule discovery and engineering, together with deep understanding of the RLT field, the company is advancing a novel pipeline focused on oncology indications with high unmet medical need. Affibody’s lead RLT candidate, ABY-271, is currently being evaluated in a first-in-human clinical study in HER2 positive metastatic breast cancer.

The Affibody® platform has also demonstrated clinical value in immunology and inflammation, with multiple programs being advanced through strategic partnerships. 

Affibody’s main shareholder Patricia Industries is a part of Investor AB.

Further information can be found at: www.affibody.com.

Contacts:

Affibody
David Bejker, CEO, +46 706 454 948
Peter Zerhouni, CFO and CBO, +46 706 420 044
 
Affibody Media Contact
Richard Hayhurst/Ola Björkman, 59° North Communications, +44 7711 821 527, richard.hayhurst@59north.bio

Cision View original content:https://www.prnewswire.com/news-releases/affibody-accelerates-phase-1-study-with-aby-271-following-initial-patient-data-302642443.html

SOURCE Affibody AB

Piyasa Fırsatı
1 Logosu
1 Fiyatı(1)
$0.006433
$0.006433$0.006433
+33.13%
USD
1 (1) Canlı Fiyat Grafiği
Sorumluluk Reddi: Bu sitede yeniden yayınlanan makaleler, halka açık platformlardan alınmıştır ve yalnızca bilgilendirme amaçlıdır. MEXC'nin görüşlerini yansıtmayabilir. Tüm hakları telif sahiplerine aittir. Herhangi bir içeriğin üçüncü taraf haklarını ihlal ettiğini düşünüyorsanız, kaldırılması için lütfen service@support.mexc.com ile iletişime geçin. MEXC, içeriğin doğruluğu, eksiksizliği veya güncelliği konusunda hiçbir garanti vermez ve sağlanan bilgilere dayalı olarak alınan herhangi bir eylemden sorumlu değildir. İçerik, finansal, yasal veya diğer profesyonel tavsiye niteliğinde değildir ve MEXC tarafından bir tavsiye veya onay olarak değerlendirilmemelidir.

Ayrıca Şunları da Beğenebilirsiniz

Crucial Insights: Two Fed Interest Rate Cuts on the Horizon?

Crucial Insights: Two Fed Interest Rate Cuts on the Horizon?

BitcoinWorld Crucial Insights: Two Fed Interest Rate Cuts on the Horizon? The financial world is buzzing with discussions around the future of monetary policy, and a recent statement from a key Federal Reserve official has added fuel to the fire. Investors, businesses, and consumers alike are keenly watching for signals regarding potential Fed interest rate cuts and their broader economic implications. What’s Driving Talk of Fed Interest Rate Cuts? Neel Kashkari, the president of the Minneapolis Federal Reserve Bank, recently made headlines by stating his belief that two additional Fed interest rate cuts would be appropriate this year. This isn’t the first time Kashkari has shared this perspective; he expressed a similar view back in August. His comments offer a glimpse into the ongoing internal debates and varying outlooks among policymakers regarding the optimal path for the nation’s economy. Understanding the context behind such statements is crucial. The Federal Reserve uses interest rates as a primary tool to manage inflation and support employment. When inflation is high, the Fed typically raises rates to cool down economic activity. Conversely, when economic growth slows or inflation targets are met, the Fed might consider cutting rates to stimulate spending and investment. How Do Fed Interest Rate Cuts Impact You? The prospect of Fed interest rate cuts carries significant weight for everyone. For instance, lower interest rates generally translate to: Cheaper Borrowing: Mortgages, car loans, and credit card interest rates can decrease, making it more affordable for consumers to borrow money. This can encourage home buying and larger purchases. Business Investment: Companies find it less expensive to borrow for expansion, new projects, and hiring, potentially boosting economic growth and job creation. Stock Market Performance: Lower rates can make bonds less attractive, pushing investors towards stocks, which might see increased valuations. This can also signal a more optimistic economic outlook. Savings Account Returns: On the flip side, interest rates on savings accounts and Certificates of Deposit (CDs) might also fall, offering lower returns for savers. These ripple effects touch various sectors, from housing to retail, and even extend into the cryptocurrency markets, where investor sentiment is often influenced by broader economic conditions and liquidity. Navigating the Economic Landscape: Why Are Policymakers Divided on Fed Interest Rate Cuts? While some policymakers, like Kashkari, see the appropriateness of multiple Fed interest rate cuts, others may hold different views. The Federal Reserve’s decisions are complex, balancing the need to control inflation with the goal of maintaining maximum employment. Key factors influencing these decisions include: Inflation Data: The pace at which inflation is returning to the Fed’s 2% target is a primary concern. Sustained progress is needed. Employment Figures: A strong job market might give the Fed more leeway to keep rates higher for longer, whereas signs of weakness could prompt cuts. Global Economic Conditions: International economic trends and geopolitical events can also influence the Fed’s domestic policy decisions. Market Expectations: The Fed also considers how financial markets are pricing in future rate movements, aiming to avoid undue volatility. The path forward is rarely straightforward, and the Fed’s approach is often described as data-dependent, meaning decisions can shift as new economic information becomes available. The Outlook for Future Fed Interest Rate Cuts Kashkari’s consistent view on two Fed interest rate cuts this year provides an important perspective, but it’s essential to remember that he is one voice among many on the Federal Open Market Committee (FOMC). The committee as a whole determines monetary policy through a consensus-driven process. As the year progresses, market participants will be closely monitoring upcoming inflation reports, employment data, and official Fed statements for further clarity. The timing and magnitude of any potential rate adjustments will significantly shape the economic environment, influencing everything from investment strategies to everyday household budgets. In summary: Neel Kashkari’s consistent advocacy for two Fed interest rate cuts this year highlights a potential shift in monetary policy. These cuts, if they materialize, could offer relief to borrowers, stimulate economic activity, and impact various markets. However, the ultimate decision rests with the broader Federal Reserve committee, which weighs a multitude of economic indicators before acting. Frequently Asked Questions (FAQs) Q1: What does it mean when the Fed cuts interest rates? When the Federal Reserve cuts interest rates, it generally means they are reducing the cost for banks to borrow money. This, in turn, often leads to lower interest rates for consumers and businesses on loans like mortgages, car loans, and credit cards, aiming to stimulate economic activity. Q2: Why would the Fed consider two Fed interest rate cuts this year? The Fed might consider two interest rate cuts if they believe inflation is consistently moving towards their 2% target, or if there are signs of slowing economic growth that could benefit from stimulation. Policymakers like Kashkari may feel the current rates are too restrictive given the economic outlook. Q3: How quickly do Fed interest rate cuts affect the economy? The effects of Fed interest rate cuts can be seen relatively quickly in financial markets, but they typically take several months to fully filter through to the broader economy, impacting consumer spending, business investment, and inflation. Q4: Will Fed interest rate cuts impact my cryptocurrency investments? While not a direct impact, Fed interest rate cuts can indirectly affect cryptocurrency markets. Lower traditional interest rates might make riskier assets like cryptocurrencies more attractive to investors seeking higher returns. Additionally, a more liquid and stimulated economy can sometimes boost overall market sentiment, benefiting crypto assets. Q5: Who is Neel Kashkari? Neel Kashkari is the president of the Federal Reserve Bank of Minneapolis. He is one of the twelve regional Federal Reserve Bank presidents who contribute to the Federal Open Market Committee (FOMC) discussions, which set the nation’s monetary policy. Did you find this article insightful? Share your thoughts and help others understand the potential impact of future Fed decisions! You can share this article on your favorite social media platforms. To learn more about the latest crypto market trends, explore our article on key developments shaping Bitcoin price action. This post Crucial Insights: Two Fed Interest Rate Cuts on the Horizon? first appeared on BitcoinWorld.
Paylaş
Coinstats2025/09/19 19:35
US Senators Introduce SAFE Crypto Act to Target Rising Crypto Scams

US Senators Introduce SAFE Crypto Act to Target Rising Crypto Scams

The post US Senators Introduce SAFE Crypto Act to Target Rising Crypto Scams appeared first on Coinpedia Fintech News Crypto scams are getting faster, smarter and
Paylaş
CoinPedia2025/12/17 18:33
Crypto.com Data Leak Revealed: Hidden Attack Exposed by Bloomberg

Crypto.com Data Leak Revealed: Hidden Attack Exposed by Bloomberg

Bloomberg exposes Crypto.com’s 2023 user data leak. The perpetrators used phishing to access employee accounts, compromising privacy. A data breach that occurred in 2023 at Crypto.com compromised the personal information of its users, according to a disclosure by Bloomberg.  The hacking was planned by a well-known hacker organization known as Scattered Spider.  This team was […] The post Crypto.com Data Leak Revealed: Hidden Attack Exposed by Bloomberg appeared first on Live Bitcoin News.
Paylaş
LiveBitcoinNews2025/09/23 03:00